|Bid||174.26 x 800|
|Ask||177.97 x 800|
|Day's Range||172.35 - 179.29|
|52 Week Range||41.77 - 182.28|
|Beta (5Y Monthly)||1.28|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 09, 2021 - Aug. 13, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||176.20|
Provides Incremental Reimbursement in Hospital Outpatient SettingSANTA CLARA, Calif., June 11, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the Centers for Medicare & Medicaid Services (CMS) granted approval for a Transitional Pass-Through (TPT) payment for Shockwave C2 Coronary IVL device, effective July 1, 2021. The TPT status provides inc
We feel now is a pretty good time to analyse ShockWave Medical, Inc.'s ( NASDAQ:SWAV ) business as it appears the...
The health tech specialist could save lives -- and deliver impressive growth to shareholders along the way.